<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138238</url>
  </required_header>
  <id_info>
    <org_study_id>SMT CT 2019-20/108</org_study_id>
    <nct_id>NCT04138238</nct_id>
  </id_info>
  <brief_title>Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent</brief_title>
  <official_title>Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Sirolimus-eluting Coronary Stent System in the Treatment of All-comer Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahajanand Medical Technologies Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular European Research Center (CERC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahajanand Medical Technologies Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, open-label, single-arm registry. The primary objective of
      this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer
      patients (800 patients as in the Supraflex arm of the TALENT trial) and demonstrate that the
      Supraflex Cruz stent is not inferior to the BioFreedom stent in High Bleeding Risk (HBR)
      patients (400 patients) with respect to device oriented composite endpoint (DOCE) at 12
      months. All patients will be followed up to 12 months after the index procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Device Oriented Composite Endpoint (DOCE)</measure>
    <time_frame>12 months</time_frame>
    <description>DOCE is a composite of cardiovascular death, myocardial infarction (MI) not clearly attributable to a non-target vessel and clinically-driven target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All death, cardiovascular death and non-cardiovascular death</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All myocardial infarction (MI)</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI and MI not clearly attributable to non-target vessel</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target lesion revascularization (TLR)</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All target lesion revascularization (TLR)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Clinically and non-clinically indicated target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All target vessel revascularization (TVR)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Clinically and non-clinically indicated target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All revascularization</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Any revascularization, TLR (clinically and non-clinically), TVR (clinically and non-clinically) and non-TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (ARC2)</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Up to 1 Day</time_frame>
    <description>Defined as deployment of the stents without system failure or device-related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>Up to 1 Day</time_frame>
    <description>Defined as the attainment of &lt; 50% residual stenosis of the target lesions post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Defined as all lesion successfully treated without the occurrence of DOCE during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding (BARC 3 to 5) in the HBR population</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Supraflex Cruz Sirolimus-eluting Stent</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supraflex Cruz Sirolimus-eluting Stent</intervention_name>
    <description>Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care</description>
    <arm_group_label>Supraflex Cruz Sirolimus-eluting Stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All-comer patients affected by silent ischemia, stable angina or acute coronary syndrome
        (unstable angina and non-STEMI), who qualify for percutaneous coronary intervention (PCI),
        400 patients of the population must qualify for HBR criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years old

          2. De novo or re-stenotic significant stenosis in at least one native coronary artery

          3. Patients with silent ischemia, stable angina, unstable angina or non-STEMI eligible
             for PCI (no limitation of the number of treated lesions and vessels, except higher
             tercile of Syntax score assessed by the site)

          4. Target lesions suitable for PCI with Drug-eluting Stent (DES) diameter between 2.00
             and 4.50 mm

          5. Total lesion length should be from 15 to 120 mm

          6. Patient is willing and capable to sign the written informed consent and comply with
             all requirements of the registry

          7. Planned staged procedures are allowed within 3 months using Supraflex Cruz stent only

        Exclusion Criteria:

          1. SYNTAX Score &gt; 32

          2. Hemodynamic instability or cardiogenic shock

          3. Known hypersensitivity or contraindication to any component of the study stent or the
             eluting drug, to media contrast, to dual antiplatelet therapy (DAPT) medication
             required by current practice

          4. Subject is pregnant, nursing or is a woman with child-bearing potential

          5. Any co-morbid condition with life expectancy &lt; 1 year or that may result in protocol
             non-compliance

          6. Patients who are participating in another drug or device investigational study, which
             has not reached its primary endpoint

          7. Patients under judicial protection, tutorship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Christoph K Naber, PD. Dr. Med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Wilhelmshaven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florian Irague</last_name>
    <phone>+33 (0) 176739254</phone>
    <email>firague@cerc-europe.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Guenther</last_name>
    <phone>+496033.972453-0</phone>
    <email>f.guenther@smtpl.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grand Hôpital de l'Est Francilien - CH de Lagny Marne la Vallée</name>
      <address>
        <city>Jossigny</city>
        <zip>77600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Cardivasculaire Paris Sud</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Claude Galien</name>
      <address>
        <city>Quincy-sous-Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Heart Center</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart and Diabetes Center Nordrhine Westfalia</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Segeberg Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden - Universitätklinikum an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elizabeth Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UKSH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss, Lukaskrankenhaus</name>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel Klinik für Kardiologie</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University and Hospital Fribourg</name>
      <address>
        <city>Fribourg</city>
        <zip>1700</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Supraflex Cruz</keyword>
  <keyword>Sirolimus-eluting Stent</keyword>
  <keyword>High Bleeding Risk</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Arteriosclerosis</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Coronary Intervention</keyword>
  <keyword>Observational Registry</keyword>
  <keyword>Ultra-thin Strut Biodegradable Polymer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

